Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479999
Status:
COMPLETED
Last Update Posted:
2019-12-16
First Post:
2007-05-26
Brief Title:
Phase 1 Safety Study of Two Experimental HIV Vaccines
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
VRC 012 A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults
Status:
COMPLETED
Status Verified Date:
2014-05-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test whether two experimental HIV vaccines are safe and whether they cause any side effects in healthy adults It will examine the body s immune response to the vaccines and monitor the social impact if any of being in an HIV vaccine study The experimental vaccines in this study are the VRC-HIVADV027-00-VP also called the rAd35-EnvA vaccine and VRC-HIVADV038-00-VP also called the rAd5-EnvA vaccine The vaccines are made using an adenovirus virus that normally causes respiratory infections and colds that has been modified to contain DNA that codes for HIV proteins The vaccines cannot cause HIV or adenoviral infections
Healthy normal volunteers between 18 and 50 years of age may be eligible for this 2-part study Part 1 includes 15 people Part 2 includes 20 people
Part 1 participants receive only the rAd35-EnvA vaccine The first five people enrolled receive the lowest study dose of the vaccine If this dose is safe then the next five people enrolled receive a higher dose If this dose is safe then the last 5 people enrolled receive the highest study dose Subjects in Part I have about five clinic visits over 24 weeks
Part II of the study starts after all injections in Part 1 are given Subjects in Part 2 are randomly assigned to one of two vaccination schedules One group receives the rAd35-EnvA vaccine first followed 12 weeks later with the rAd5-EnvA vaccine The other group receives the vaccines in reverse order that is first the rAd5-EnvA vaccine followed 12 weeks later with the rAd35-EnvA vaccine In this schedule the first vaccination primes the immune system and then the immune response is boosted 12 weeks later with a different vaccine Everyone in study Part 2 receives the rAd35-EnvA vaccine at the middle dose tested in Part 1 Subjects in Part 2 have about eight clinic visits over 36 weeks
All vaccinations are given as injections in the upper arm At each clinic visit participants are checked for health changes or problems They are asked how they are feeling and if they have taken any medications Urine samples are collected and blood is drawn at some visits They are tested for HIV several times and asked questions about their sexual behavior and drug use Throughout the study participants are counseled on HIV risk reduction Subjects are asked about any social effects they may have experienced from their participation in this study
Healthy normal volunteers between 18 and 50 years of age may be eligible for this 2-part study Part 1 includes 15 people Part 2 includes 20 people
Part 1 participants receive only the rAd35-EnvA vaccine The first five people enrolled receive the lowest study dose of the vaccine If this dose is safe then the next five people enrolled receive a higher dose If this dose is safe then the last 5 people enrolled receive the highest study dose Subjects in Part I have about five clinic visits over 24 weeks
Part II of the study starts after all injections in Part 1 are given Subjects in Part 2 are randomly assigned to one of two vaccination schedules One group receives the rAd35-EnvA vaccine first followed 12 weeks later with the rAd5-EnvA vaccine The other group receives the vaccines in reverse order that is first the rAd5-EnvA vaccine followed 12 weeks later with the rAd35-EnvA vaccine In this schedule the first vaccination primes the immune system and then the immune response is boosted 12 weeks later with a different vaccine Everyone in study Part 2 receives the rAd35-EnvA vaccine at the middle dose tested in Part 1 Subjects in Part 2 have about eight clinic visits over 36 weeks
All vaccinations are given as injections in the upper arm At each clinic visit participants are checked for health changes or problems They are asked how they are feeling and if they have taken any medications Urine samples are collected and blood is drawn at some visits They are tested for HIV several times and asked questions about their sexual behavior and drug use Throughout the study participants are counseled on HIV risk reduction Subjects are asked about any social effects they may have experienced from their participation in this study
Detailed Description:
Study Design
The VRC recombinant adenoviral vector serotype 5 rAd5 multiclade vaccine has been previously shown to elicit immune responses to HIV-1-specific peptides when administered intramuscularly IM alone and in prime-boost schedules with the greatest magnitude and frequency of response to the Envelope A immunogen EnvA
Part I of this study is an open label dose escalation evaluation of an HIV-1 adenoviral vector serotype 35 vaccine rAd35-EnvA
Subjects in Group 1 will receive one vaccination of rAd35-EnvA 109 PU
Subjects in Group 2 will receive one vaccination of rAd35-EnvA 1010 PU
Subjects in Group 3 will receive one vaccination of rAd35-EnvA 1011 PU
Part II Group 4 of this study is a randomized double blind evaluation of the rAd35-EnvA vaccine in comparison to and in combination with a rAd5-EnvA vaccine in prime-boost schedules
The hypotheses are 1 rAd35-EnvA vaccine will be safe for human administration at dosages up to 1011 PU as a single agent and both the rAd35-EnvA and rAd5-EnvA vaccines will be safe in prime-boost regimens 2 both the rAd35-EnvA and rAd5-EnvA vaccines will elicit immune responses to the EnvA immunogen and 3 the heterologous prime-boost regimens will elicit a greater frequency and magnitude of response than after the priming vaccinations alone The primary objectives relate to evaluation of the safety and tolerability of the rAd35-EnvA and rAd5-EnvA vaccines Secondary objectives are related to evaluation of the immunogenicity of the vaccines when comparing rAd35-EnvA to rAd5-EnvA when administered as a prime or as a boost vaccination
Product Description Both the VRC-HIVADV038-00-VP rAd5-EnvA and the VRC-HIVADV027-00-VP rAd35-EnvA vaccines are composed of recombinant replication deficient adenoviral vectors that encode for HIV-1 clade A Env glycoprotein
Subjects Thirty-five healthy adult volunteers 18 to 50 years old beginning with the Version 20 protocol subjects in Part I must be Ad35 antibody Ab seronegative and subjects in Part II must be both Ad5- and Ad35-seronegative
Study Plan Part I Fifteen subjects will receive an open-label 1 mL IM deltoid injection via needle and syringe of the study agent No more than one subject per day will be enrolled into each dose group Five days following vaccination of the fifth volunteer in each dose group there will be an internal safety review including the principal investigator clinical team and medical officer to determine whether to proceed to next dose level
Part II Initiation of enrollment into Part II will be contingent upon completion of enrollment into Group 3 and a safety review of 109 and 1010 PU dosage by the Data and Safety Monitoring Board DSMB The safety review will take place when at least 2 weeks of follow-up on the last 1010 PU injection in Group 2 is available in the safety reports the DSMB safety review may occur during enrollment of Group 3
Enrollment into Group 4 will be randomized and double-blinded The first 10 subjects in Group 4 will be randomized in a 11 ratio into heterologous prime-boost vaccination schedules in which both rAd5-EnvA and rAd35-EnvA are administered at the 1010 PU dosage The last 10 subjects in Group 4 will be randomized in a 11 ratio into heterologous prime-boost vaccination schedules in which the rAd5-EnvA is administered at 1010 PU and rAd35-EnvA is administered at 1011 PU All subjects will receive each study agent administered as 1 mL IM deltoid injections 12 weeks apart according to the schedule
Study Duration
The vaccination regimen and clinical follow-up schedule for Part I requires 24 weeks and for Part II requires 52 weeks to complete Part II subjects will be contacted annually for 4 years after study completion for collection of long-term follow-up information
The VRC recombinant adenoviral vector serotype 5 rAd5 multiclade vaccine has been previously shown to elicit immune responses to HIV-1-specific peptides when administered intramuscularly IM alone and in prime-boost schedules with the greatest magnitude and frequency of response to the Envelope A immunogen EnvA
Part I of this study is an open label dose escalation evaluation of an HIV-1 adenoviral vector serotype 35 vaccine rAd35-EnvA
Subjects in Group 1 will receive one vaccination of rAd35-EnvA 109 PU
Subjects in Group 2 will receive one vaccination of rAd35-EnvA 1010 PU
Subjects in Group 3 will receive one vaccination of rAd35-EnvA 1011 PU
Part II Group 4 of this study is a randomized double blind evaluation of the rAd35-EnvA vaccine in comparison to and in combination with a rAd5-EnvA vaccine in prime-boost schedules
The hypotheses are 1 rAd35-EnvA vaccine will be safe for human administration at dosages up to 1011 PU as a single agent and both the rAd35-EnvA and rAd5-EnvA vaccines will be safe in prime-boost regimens 2 both the rAd35-EnvA and rAd5-EnvA vaccines will elicit immune responses to the EnvA immunogen and 3 the heterologous prime-boost regimens will elicit a greater frequency and magnitude of response than after the priming vaccinations alone The primary objectives relate to evaluation of the safety and tolerability of the rAd35-EnvA and rAd5-EnvA vaccines Secondary objectives are related to evaluation of the immunogenicity of the vaccines when comparing rAd35-EnvA to rAd5-EnvA when administered as a prime or as a boost vaccination
Product Description Both the VRC-HIVADV038-00-VP rAd5-EnvA and the VRC-HIVADV027-00-VP rAd35-EnvA vaccines are composed of recombinant replication deficient adenoviral vectors that encode for HIV-1 clade A Env glycoprotein
Subjects Thirty-five healthy adult volunteers 18 to 50 years old beginning with the Version 20 protocol subjects in Part I must be Ad35 antibody Ab seronegative and subjects in Part II must be both Ad5- and Ad35-seronegative
Study Plan Part I Fifteen subjects will receive an open-label 1 mL IM deltoid injection via needle and syringe of the study agent No more than one subject per day will be enrolled into each dose group Five days following vaccination of the fifth volunteer in each dose group there will be an internal safety review including the principal investigator clinical team and medical officer to determine whether to proceed to next dose level
Part II Initiation of enrollment into Part II will be contingent upon completion of enrollment into Group 3 and a safety review of 109 and 1010 PU dosage by the Data and Safety Monitoring Board DSMB The safety review will take place when at least 2 weeks of follow-up on the last 1010 PU injection in Group 2 is available in the safety reports the DSMB safety review may occur during enrollment of Group 3
Enrollment into Group 4 will be randomized and double-blinded The first 10 subjects in Group 4 will be randomized in a 11 ratio into heterologous prime-boost vaccination schedules in which both rAd5-EnvA and rAd35-EnvA are administered at the 1010 PU dosage The last 10 subjects in Group 4 will be randomized in a 11 ratio into heterologous prime-boost vaccination schedules in which the rAd5-EnvA is administered at 1010 PU and rAd35-EnvA is administered at 1011 PU All subjects will receive each study agent administered as 1 mL IM deltoid injections 12 weeks apart according to the schedule
Study Duration
The vaccination regimen and clinical follow-up schedule for Part I requires 24 weeks and for Part II requires 52 weeks to complete Part II subjects will be contacted annually for 4 years after study completion for collection of long-term follow-up information
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 07-I-0167 | None | None | None |